BACKGROUND:Cancer chemotherapy is frequently associated with a decline in general physical condition, exercise tolerance, and muscle strength and with an increase in fatigue. While accumulating evidence suggests that physical activity and exercise interventions during chemotherapy treatment may contribute to maintaining cardiorespiratory fitness and strength, the results of studies conducted to date have not been consistent. Additional research is needed to determine the optimal intensity of exercise training programs in general and in particular the relative effectiveness of supervised, outpatient (hospital- or physical therapy practice-based) versus home-based programs. METHODS: This multicenter, prospective, randomized trial will evaluate the effectiveness of a low to moderate intensity, home-based, self-management physical activity program, and a high intensity, structured, supervised exercise program, in maintaining or enhancing physical fitness (cardiorespiratory fitness and muscle strength), in minimizing fatigue and in enhancing the health-related quality of life (HRQoL). Patients receiving adjuvant chemotherapyfor breast or colon cancer (n = 360) are being recruited from twelve hospitals in the Netherlands, and randomly allocated to one of the two treatment groups or to a 'usual care' control group. Performance-based and self-reported outcomes are assessed at baseline, at the end of chemotherapy and at six month follow-up. DISCUSSION: This large, multicenter, randomized clinical trial will provide additional empirical evidence regarding the effectiveness of physical exercise during adjuvant chemotherapy in enhancing physical fitness, minimizing fatigue, and maintaining or enhancing patients' quality of life. If demonstrated to be effective, exercise intervention programs will be a welcome addition to the standard program of care offered to patients with cancer receiving chemotherapy. TRIAL REGISTRATION: This study is registered at the Netherlands Trial Register (NTR 2159).
RCT Entities:
BACKGROUND:Cancer chemotherapy is frequently associated with a decline in general physical condition, exercise tolerance, and muscle strength and with an increase in fatigue. While accumulating evidence suggests that physical activity and exercise interventions during chemotherapy treatment may contribute to maintaining cardiorespiratory fitness and strength, the results of studies conducted to date have not been consistent. Additional research is needed to determine the optimal intensity of exercise training programs in general and in particular the relative effectiveness of supervised, outpatient (hospital- or physical therapy practice-based) versus home-based programs. METHODS: This multicenter, prospective, randomized trial will evaluate the effectiveness of a low to moderate intensity, home-based, self-management physical activity program, and a high intensity, structured, supervised exercise program, in maintaining or enhancing physical fitness (cardiorespiratory fitness and muscle strength), in minimizing fatigue and in enhancing the health-related quality of life (HRQoL). Patients receiving adjuvant chemotherapy for breast or colon cancer (n = 360) are being recruited from twelve hospitals in the Netherlands, and randomly allocated to one of the two treatment groups or to a 'usual care' control group. Performance-based and self-reported outcomes are assessed at baseline, at the end of chemotherapy and at six month follow-up. DISCUSSION: This large, multicenter, randomized clinical trial will provide additional empirical evidence regarding the effectiveness of physical exercise during adjuvant chemotherapy in enhancing physical fitness, minimizing fatigue, and maintaining or enhancing patients' quality of life. If demonstrated to be effective, exercise intervention programs will be a welcome addition to the standard program of care offered to patients with cancer receiving chemotherapy. TRIAL REGISTRATION: This study is registered at the Netherlands Trial Register (NTR 2159).
Authors: Hidde P van der Ploeg; Kitty R M Streppel; Allard J van der Beek; Luc H V van der Woude; Miriam M R Vollenbroek-Hutten; Wim H van Harten; Willem van Mechelen Journal: Am J Health Promot Date: 2007 Jan-Feb
Authors: Ingrid C De Backer; Goof Schep; Adwin Hoogeveen; Gerard Vreugdenhil; Arnold D Kester; Eric van Breda Journal: Arch Phys Med Rehabil Date: 2007-05 Impact factor: 3.966
Authors: Iris J G Ketel; Mariken N M Volman; Jacob C Seidell; Coen D A Stehouwer; Jos W Twisk; Cornelis B Lambalk Journal: Eur J Endocrinol Date: 2007-06 Impact factor: 6.664
Authors: Nanette Mutrie; Anna M Campbell; Fiona Whyte; Alex McConnachie; Carol Emslie; Laura Lee; Nora Kearney; Andrew Walker; Diana Ritchie Journal: BMJ Date: 2007-02-16
Authors: Hanna van Waart; Johanna M van Dongen; Wim H van Harten; Martijn M Stuiver; Rosalie Huijsmans; Jeannette A J H Hellendoorn-van Vreeswijk; Gabe S Sonke; Neil K Aaronson Journal: Eur J Health Econ Date: 2017-10-30
Authors: Hanna van Waart; Martijn M Stuiver; Wim H van Harten; Edwin Geleijn; Marianne de Maaker-Berkhof; Jolanda Schrama; Maud M Geenen; Jetske M Meerum Terwogt; Simone M van den Heiligenberg; Jeannette A J H Hellendoorn-van Vreeswijk; Gabe S Sonke; Neil K Aaronson Journal: Int J Colorectal Dis Date: 2017-11-09 Impact factor: 2.571
Authors: Shiraz I Mishra; Roberta W Scherer; Claire Snyder; Paula M Geigle; Debra R Berlanstein; Ozlem Topaloglu Journal: Cochrane Database Syst Rev Date: 2012-08-15
Authors: Hanna van Waart; Laurien M Buffart; Martijn M Stuiver; Wim H van Harten; Gabe S Sonke; Neil K Aaronson Journal: Support Care Cancer Date: 2019-08-08 Impact factor: 3.603
Authors: Jeanne S Mandelblatt; Gheorghe Luta; Marilyn L Kwan; Solomon B Makgoeng; Isaac J Ergas; Janise M Roh; Barbara Sternfeld; Lucile L Adams-Campbell; Lawrence H Kushi Journal: Breast Cancer Res Treat Date: 2011-04-08 Impact factor: 4.872
Authors: Mai J M Chinapaw; Laurien M Buffart; Willem van Mechelen; Goof Schep; Neil K Aaronson; Wim H van Harten; Martijn M Stuiver; Marie José Kersten; Frans Nollet; Gertjan J L Kaspers; Eline van Dulmen-den Broeder; Jaap Huisman; Tim Takken; Maurits van Tulder; Johannes Brug Journal: Int J Behav Med Date: 2012-06
Authors: Corina S Rueegg; Gisela Michel; Laura Wengenroth; Nicolas X von der Weid; Eva Bergstraesser; Claudia E Kuehni Journal: PLoS One Date: 2012-10-17 Impact factor: 3.240